StreetInsider.com News Articles

Soleno Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SLNO

Thu, 12 Mar 2026 04:40:00 -0400

LOS ANGELES, March 12, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Soleno Therapeutics, Inc. ("Soleno" or "the Company") (NASDAQ: SLNO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of SLNO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not

Soleno Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SLNO

Thu, 12 Mar 2026 04:40:00 -0400

Shareholders who purchased shares of SLNO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not

Soleno Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SLNO

Thu, 12 Mar 2026 04:40:00 -0400

Shareholders who purchased shares of SLNO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not

Soleno Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SLNO

Thu, 12 Mar 2026 04:40:00 -0400

Shareholders who purchased shares of SLNO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not

Soleno Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SLNO

Thu, 12 Mar 2026 04:40:00 -0400

Shareholders who purchased shares of SLNO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not

Soleno Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SLNO

Thu, 12 Mar 2026 04:40:00 -0400

Shareholders who purchased shares of SLNO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not

Soleno Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SLNO

Thu, 12 Mar 2026 04:40:00 -0400

Shareholders who purchased shares of SLNO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not

Soleno Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SLNO

Thu, 12 Mar 2026 04:40:00 -0400

Shareholders who purchased shares of SLNO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not

Soleno Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Soleno Therapeutics, Inc. - SLNO

Wed, 11 Mar 2026 21:36:00 -0400

NEW ORLEANS, March 11, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 5, 2026 to file lead plaintiff applications in a securities class action lawsuit against Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NasdaqCM: SLNO), if they purchased or otherwise acquired the Company’s shares between March 26, 2025 and November 4, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.

Get Help

Soleno investors

Soleno Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Soleno Therapeutics, Inc. - SLNO

Wed, 11 Mar 2026 21:36:00 -0400

Get Help

Soleno investors

Soleno Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Soleno Therapeutics, Inc. - SLNO

Wed, 11 Mar 2026 21:36:00 -0400

Get Help

Soleno investors

Soleno Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Soleno Therapeutics, Inc. - SLNO

Wed, 11 Mar 2026 21:36:00 -0400

Get Help

Soleno investors

Soleno Therapeutics, Inc. Notice of May 5, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Tue, 10 Mar 2026 22:35:00 -0400

NEW YORK and NEW ORLEANS, March 10, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NasdaqCM: SLNO) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors of Soleno Therapeutics who were adversely affected by alleged securities fraud between March 26, 2025 and November 4, 2025. Follow the link below to get more information and

Soleno Therapeutics, Inc. Notice of May 5, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Tue, 10 Mar 2026 22:35:00 -0400

Soleno Therapeutics, Inc. Notice of May 5, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Tue, 10 Mar 2026 22:35:00 -0400

Soleno Therapeutics, Inc. Notice of May 5, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Tue, 10 Mar 2026 22:35:00 -0400

Portnoy Law Firm Announces Class Action on Behalf of Soleno Therapeutics, Inc. Investors

Tue, 10 Mar 2026 00:00:00 -0400

LOS ANGELES, March 10, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Soleno Therapeutics, Inc., (“Soleno” or the "Company") (NASDAQ: SLNO) investors off a class action on behalf of investors that bought securities between March 6, 2025 and November 4, 2025, inclusive (the “Class Period”). Soleno investors have until May 5, 2026 to file a lead plaintiff motion.

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or join the case via

Portnoy Law Firm Announces Class Action on Behalf of Soleno Therapeutics, Inc. Investors

Tue, 10 Mar 2026 00:00:00 -0400

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or join the case via

Portnoy Law Firm Announces Class Action on Behalf of Soleno Therapeutics, Inc. Investors

Tue, 10 Mar 2026 00:00:00 -0400

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or join the case via

Portnoy Law Firm Announces Class Action on Behalf of Soleno Therapeutics, Inc. Investors

Tue, 10 Mar 2026 00:00:00 -0400

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or join the case via

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Soleno Therapeutics, Inc. (SLNO)

Mon, 09 Mar 2026 12:44:00 -0400

NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities who purchased or otherwise acquired Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ: SLNO) securities between March 26, 2025 and November 4, 2025, inclusive (the “Class Period”).

The Complaint alleges that Defendants failed to disclose to investors that: (a) that the Soleno Phase 3 clinical trial program for DCCR had systematically downplayed, misrepresented, and/or

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Soleno Therapeutics, Inc. (SLNO)

Mon, 09 Mar 2026 12:44:00 -0400

The Complaint alleges that Defendants failed to disclose to investors that: (a) that the Soleno Phase 3 clinical trial program for DCCR had systematically downplayed, misrepresented, and/or

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Soleno Therapeutics, Inc. (SLNO)

Mon, 09 Mar 2026 12:44:00 -0400

The Complaint alleges that Defendants failed to disclose to investors that: (a) that the Soleno Phase 3 clinical trial program for DCCR had systematically downplayed, misrepresented, and/or

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Soleno Therapeutics, Inc. (SLNO)

Mon, 09 Mar 2026 12:44:00 -0400

The Complaint alleges that Defendants failed to disclose to investors that: (a) that the Soleno Phase 3 clinical trial program for DCCR had systematically downplayed, misrepresented, and/or

Form 4 SOLENO THERAPEUTICS INC For: Mar 02 Filed by: Fulk Jennifer

Wed, 04 Mar 2026 18:00:00 -0400

si-local-file:///var/storage/secattach/20260304/26113095.html